Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

PaperCitations, authors & open-access status
2,290
Citations
2,017
Year
green
OA Status
Related on ScholarIQ
The Lancet
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account